La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Kiora Pharmaceuticals Croissance future

Future contrôle des critères 0/6

Les revenus et les bénéfices de Kiora Pharmaceuticals devraient diminuer respectivement de 13.4% et de 34.6% par an, tandis que le BPA devrait croître de diminuer de 33.8% par an.

Informations clés

-34.6%

Taux de croissance des bénéfices

-33.8%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	23.6%
Taux de croissance des recettes	-13.4%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	12 Aug 2024

Mises à jour récentes de la croissance future

Recent updates

Why Kiora Pharmaceuticals' (NASDAQ:KPRX) Earnings Are Better Than They Seem

May 21

Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

Oct 13

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:KPRX - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	1	-15	N/A	N/A	2
12/31/2025	2	-11	N/A	N/A	3
12/31/2024	17	7	N/A	N/A	2
6/30/2024	16	3	5	5	N/A
3/31/2024	16	2	7	7	N/A
12/31/2023	N/A	-13	-10	-10	N/A
9/30/2023	N/A	-13	-9	-9	N/A
6/30/2023	N/A	-12	-10	-10	N/A
3/31/2023	N/A	-12	-11	-11	N/A
12/31/2022	N/A	-14	-10	-10	N/A
9/30/2022	N/A	-17	-11	-11	N/A
6/30/2022	N/A	-15	-11	-11	N/A
3/31/2022	N/A	-15	-11	-11	N/A
12/31/2021	N/A	-14	-11	-11	N/A
9/30/2021	0	-9	-10	-9	N/A
6/30/2021	0	-8	-9	-9	N/A
3/31/2021	0	-7	-8	-7	N/A
12/31/2020	0	-7	-7	-7	N/A
9/30/2020	N/A	-8	-8	-8	N/A
6/30/2020	N/A	-10	-8	-8	N/A
3/31/2020	N/A	-10	-8	-8	N/A
12/31/2019	3	-7	-8	-8	N/A
9/30/2019	3	-7	-8	-8	N/A
6/30/2019	3	-7	-9	-8	N/A
3/31/2019	3	-8	-9	-9	N/A
12/31/2018	2	-11	-11	-11	N/A
9/30/2018	2	-11	-11	-10	N/A
6/30/2018	1	-12	-10	-10	N/A
3/31/2018	1	-13	N/A	-11	N/A
12/31/2017	0	-13	N/A	-6	N/A
9/30/2017	1	-14	N/A	-7	N/A
6/30/2017	1	-13	N/A	-7	N/A
3/31/2017	1	-14	N/A	-7	N/A
12/31/2016	1	-13	N/A	-8	N/A
9/30/2016	1	-12	N/A	-8	N/A
6/30/2016	0	-10	N/A	-6	N/A
3/31/2016	N/A	-8	N/A	-4	N/A
12/31/2015	N/A	-17	N/A	-4	N/A
9/30/2015	N/A	-14	N/A	-3	N/A
6/30/2015	N/A	-13	N/A	-3	N/A
3/31/2015	N/A	-12	N/A	-2	N/A
12/31/2014	N/A	-2	N/A	-1	N/A
9/30/2014	N/A	-2	N/A	-1	N/A
6/30/2014	N/A	-3	N/A	-2	N/A
3/31/2014	N/A	-4	N/A	-3	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Les bénéfices de KPRX devraient diminuer au cours des 3 prochaines années ( -34.6% par an).

Bénéfices vs marché: Les bénéfices de KPRX devraient diminuer au cours des 3 prochaines années ( -34.6% par an).

Croissance élevée des bénéfices: Les bénéfices de KPRX devraient baisser au cours des trois prochaines années.

Chiffre d'affaires vs marché: Les revenus de KPRX devraient diminuer au cours des 3 prochaines années ( -13.4% par an).

Croissance élevée des revenus: Les revenus de KPRX devraient diminuer au cours des 3 prochaines années ( -13.4% par an).

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de KPRX devrait être élevé dans 3 ans

Kiora Pharmaceuticals Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased by 69% to US$3.83

Price target increased by 42% to US$17.50

Price target decreased by 56% to US$20.00

Price target increased by 39% to US$65.50

No longer forecast to breakeven

Price target decreased to US$11.83

Recent updates

New major risk - Market cap size

Investor sentiment deteriorates as stock falls 16%

Kiora Pharmaceuticals, Inc. Announces Board and Committee Changes

Investor sentiment improves as stock rises 21%

Why Kiora Pharmaceuticals' (NASDAQ:KPRX) Earnings Are Better Than They Seem

Kiora Pharmaceuticals, Inc., Annual General Meeting, May 01, 2024

New major risk - Revenue and earnings growth

Price target decreased by 69% to US$3.83

New major risk - Share price stability

Price target increased by 42% to US$17.50

Kiora Pharmaceuticals, Inc. Announces Board Changes

New major risk - Revenue and earnings growth

Price target decreased by 56% to US$20.00

Kiora Pharmaceuticals, Inc. Appoints Carmine Stengone as an Independent Director

Kiora Pharmaceuticals Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Price target increased by 39% to US$65.50

Kiora Pharmaceuticals, Inc. and The Royal Adelaide Hospital Announce Dosing Has Commenced in the Phase 1 First-In-Human Trial for KIO-301

Kiora Pharmaceuticals, Inc. Receives Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases

High number of new directors

Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

Kiora Pharma announces 1-for-40 reverse stock split

Kiora Pharmaceuticals, Inc. Appoints Melissa Tosca as Executive Vice President of Finance

Kiora Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

High number of new directors

Kiora Pharmaceuticals, Inc., Annual General Meeting, Sep 23, 2022

Kiora Pharmaceuticals reports 1H results

Kiora gets US patent for KIO-201 use with antibiotics for eye wound healing

Kiora Pharmaceuticals prices $5.2M underwritten public offering

Kiora begins enrolling in phase 2 trial of wound healing eye drops KIO-201

Kiora Pharmaceuticals, Inc. Announces Brian M. Strem Will Assume Role of its Principal Financial and Accounting Officer

Kiora Pharmaceuticals Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Kiora Pharmaceuticals, Inc. announced delayed 10-Q filing

Kiora Pharmaceuticals, Inc. Appoints Susan L. Drexler as Interim Chief Financial Officer

Kiora Pharmaceuticals, Inc. announced delayed annual 10-K filing

Kiora Pharmaceuticals, Inc. Appoints Michael Meluzio as Principal Financial Officer and Principal Accounting Officer

Kiora Pharmaceuticals, Inc. Announces Resignation of Sarah Romano as Chief Financial Officer, Effective February 25, 2022

Kiora Pharmaceuticals, Inc. Announces Executive Changes

No longer forecast to breakeven

EyeGate Pharmaceuticals, Inc. Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation

Price target decreased to US$11.83

EyeGate Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $10.750013 million.

Director Steven Boyd has left the company

Director I. Maher has left the company

EyeGate Pharmaceuticals, Inc. Announces First Patient Dosed for PP-001 in A Phase 2 Proof-Of-Concept Ocular Surface Inflammation Study

No longer forecast to breakeven

Price target decreased to US$13.08

Full year 2020 earnings released: US$1.77 loss per share (vs US$2.23 loss in FY 2019)

New 90-day high: US$7.30

EyeGate Pharmaceuticals, Inc. Announces Board Appointments

New 90-day high: US$6.63

EyeGate Pharmaceuticals announces $8M private placement

Price target raised to US$12.83

EyeGate Pharmaceuticals, Inc. (NasdaqCM:EYEG) entered into a share purchase agreement to acquire Panoptes Pharma GES.M.B.H for $15 million.

New 90-day high: US$5.21

EyeGate surge in premarket as it acquires Panoptes Pharma for $4M

Earnings beat expectations

New 90-day low: US$3.57

Price target lowered to US$11.17

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance